FUNDAMENTAL AND CLINICAL STUDIES OF T-1982 (CEFBUPERAZONE) IN THE FIELD OF OBSTETRICS AND GYNECOLOGY

DOI Web Site PubMed
  • IKEDA MASANORI
    Department of Obstetrics and Gynecology, Kinki University, School of Medicine
  • TESHIMA KENSAKU
    Department of Obstetrics and Gynecology, Kinki University, School of Medicine
  • NODA KIICHIRO
    Department of Obstetrics and Gynecology, Kinki University, School of Medicine

Bibliographic Information

Other Title
  • 産婦人科領域における T-1982 (Cefbuperazone) の基礎的・臨床的検討
  • サンフジンカ リョウイキ ニ オケル T 1982 Cefbuperazone

Search this article

Abstract

1. Tissue concentrations of T-1982 (cefbuperazone) at 100-220 minutes after the completion of 1g/60 minutes dripping infusion were 8.9-10.6μg/g in the uterus, ovary and oviduct. These concentrations were higher than 80% MIC of the causative organisms, including E. coli, K. pneumoniae, P. mirabilis, Bacteroides and Peptococcus isolated from infections in the field of obstetrics and gynecology.<BR>2. The T-1982 concentration in the retroperitoneal space exudate reached a peak value of 19.6μg/ml at 2 hours after the completion of 1g/60 minutes dripping infusion and decreased at a constant rate.<BR>3. We administered T-1982 at 2 g per day for a period of 7-9 days to 3 patients with gynecological infectious diseases. All cases proved to respond effectively. No side effects and abnormal laboratory findings were observed.

Journal

Details 詳細情報について

Report a problem

Back to top